Arvinas (ARVN)
(Delayed Data from NSDQ)
$31.44 USD
-0.51 (-1.60%)
Updated May 10, 2024 04:00 PM ET
After-Market: $31.46 +0.02 (0.06%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ARVN 31.44 -0.51(-1.60%)
Will ARVN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ARVN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARVN
Acadia (ACHC), Geisinger JV Begin Construction of New Hospital
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
ARVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
Why Earnings Season Could Be Great for Arvinas (ARVN)
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
Other News for ARVN
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
Arvinas price target lowered by $3 at Wells Fargo, here's why
Buy Rating Affirmed on Arvinas with Promising Trial Updates and Robust Financial Outlook
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Arvinas Holding Company (ARVN) and uniQure (QURE)
Arvinas price target lowered by $10 at Oppenheimer, here's why